Johnson & Johnson (JNJ) Liabilities from Discontinued Operations (2023)

Johnson & Johnson (JNJ) posted Liabilities from Discontinued Operations of 3590000000.0 for Q1 2023.

Johnson & Johnson (JNJ) Liabilities from Discontinued Operations (2023) Analysis & Trends

Johnson & Johnson (JNJ) has 1 years of Liabilities from Discontinued Operations data on file, last reported at 3590000000.0 in Q1 2023.

  • Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 3590000000.0 in Q1 2023, while the trailing twelve-month figure through Jan 2023 was 3590000000.0 (changed N/A YoY) and the FY2023 annual result came in at 3590000000.0, changed N/A from the prior year.
  • Liabilities from Discontinued Operations held at 3590000000.0 in Q1 2023 per JNJ's latest filing.
  • The five-year high for Liabilities from Discontinued Operations was 3590000000.0 in Q1 2023, with the low at 3590000000.0 in Q1 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn

Historic Data

Download Data
DateValue
Jan 1, 2023 3.59 Bn
Jan 1, 2023 3.59 Bn